Floatz logo

Hucart-Meso Cells

Mesothelioma Peritoneum

University of PennsylvaniaCell therapyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Mesothelioma Peritoneum cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
MITOMYCIN C
National Cancer Institute (NCI)
Phase 2B
Sodium Thiosulfate
National Cancer Institute (NCI)
Phase 2B
FLUOROURACILUM
Hospices Civils de Lyon
Phase 2B
Nivolumab
TCR2 Therapeutics
Phase 2B

View all 20 →

Same molecule, other indications

Hucart-Meso Cells is also rated in:

pleural mesotheliomaDormant
C
Indicative ·
39 / 100
View asset →
peritoneal carcinomaDormant
C
Indicative ·
39 / 100
View asset →
lung adenocarcinomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →